Equity Research Institute has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Zoetis Inc. (NYSE: ZTS), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Akorn Inc. (NASDAQ: AKRX), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN).
Mylan N.V.
On Monday, September 28, 2015, the NASDAQ Composite ended at 4,543.97, down 3.04%, the Dow Jones Industrial Average declined 1.92%, to finish the day at 16,001.89, and the S&P 500 closed at 1,881.77, down 2.57%. The losses were broad based as all the sectors ended the session in negative. Mylan N.V.’s stock declined 6.31%, to close the day at $40.86. The stock recorded a trading volume of 17.42 million shares, much above its three months average volume of 7.52 million shares. Over the last one month and over the past three months, Mylan N.V.’s shares have plummeted 20.64% and 39.58%, respectively. Furthermore, the stock has lost 27.51% since the start of this year. The company’s shares are trading 23.59% below their 50-day moving average. Additionally, Mylan N.V. traded at a PE ratio of 18.74 and has a Relative Strength Index (RSI) of 21.13.
Zoetis Inc.
On Monday, shares in Zoetis Inc. recorded a trading volume of 8.94 million shares, higher than their three months average volume of 3.65 million shares. The stock ended the day 6.00% lower at $39.96. Shares of the company traded at a PE ratio of 48.14. Zoetis Inc.’s stock has lost 12.87% in the last one month, 14.96% in the previous three months and 6.63% on YTD basis. The company is trading below its 50-day and 200-day moving averages by 13.99% and 13.37%, respectively. Furthermore, shares of Zoetis Inc. have an RSI of 28.50.
Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc.’s stock declined 3.20%, to close Monday’s session at $9.99. The stock recorded a trading volume of 1.80 million shares, above its three months average volume of 1.58 million shares. Over the last one month and the previous three months, Ironwood Pharmaceuticals Inc.’s shares have lost 9.59% and 13.81%, respectively. Additionally, the stock has plummeted 34.79% since the start of this year. The company is trading 9.78% and 26.90% below its 50-day and 200-day moving averages, respectively. Furthermore, Ironwood Pharmaceuticals Inc.’s stock has an RSI of 33.30.
Akorn Inc.
Akorn Inc.’s stock finished Monday’s session 8.64% lower at $29.29. A total of 2.38 million shares were traded, which was above its three months average volume of 1.17 million shares. Over the last one month and the previous three months, Akorn Inc.’s shares have plummeted 28.93% and 31.15%, respectively. Additionally, the stock has declined 19.09% since the beginning of 2015. The company’s shares are trading below their 50-day and 200-day moving averages by 29.71% and 33.54%, respectively. Akorn Inc.’s stock traded at a PE ratio of 91.53 and has an RSI of 18.56.
Supernus Pharmaceuticals Inc.
On Monday, shares in Supernus Pharmaceuticals Inc. ended the session 12.43% lower at $14.51. The stock reported a trading volume of 1.36 million shares, above its three months average volume of 0.90 million shares. Shares of the company traded at a PE ratio of 21.03. Supernus Pharmaceuticals Inc.’s shares have declined 17.18% in the last one month and 11.15% in the previous three months. However, the stock has surged 74.82% on YTD basis. The company is trading 5.52% above its 200-day moving average. Moreover, shares of Supernus Pharmaceuticals Inc. have an RSI of 27.13.